About BiomeBank
BiomeBank is a Healthcare company based in Thebarton (Australia) founded in 2018 by Sam Costello. Microbial therapies for disease treatment are developed using bioinformatics platforms. BiomeBank has raised $10.7 million across 1 funding round from investors including Ellerston Capital and SAVCF. Its chief executive, as recorded, is Sam Costello. BiomeBank offers products and services including BB265 Therapy, Donor-Derived Therapy, and Consortiome Platform. Its focus areas include Life Sciences, Microbiome Therapeutics, Probiotics and Infectious Diseases.
Company details
Founded in 2018 in Thebarton, Australia, microbial therapies are developed to address diseases, particularly recurrent Clostridioides difficile infections through BiomeBoost, which incorporates therapeutic microbes. A platform integrating microbiology, machine learning, and bioinformatics is utilized for discovering biomarkers, leads, and targets. Stool samples are collected to support research and development in the biotechnology sector.
- Headquarters Thebarton, Australia
- Founders Sam Costello
- SectorsHealthcare
- Website biomebank.com
- Social LinkedIn X Instagram YouTube
- Total Equity Funding$10.7M (USD)
in 1 rounds
- Latest Funding Round$10.7M (USD), Series B
Dec 2022
- InvestorsEllerston Capital
& 1 more
Products & Services of BiomeBank
BiomeBank offers a comprehensive portfolio of products and services, including BB265 Therapy, Donor-Derived Therapy, and Consortiome Platform.
Rationally designed therapy for treating Ulcerative Colitis via gut microbiome restoration.
Regulator-approved treatment for Clostridioides difficile infection in patients.
Co-culturing system for generating artificial gut microbial communities affordably.
Apps and channels of BiomeBank
its YouTube channel BiomeBank has 12 subscribers.
Funding Insights of BiomeBank
BiomeBank has successfully raised a total of $10.7M through 1 strategic funding round. The most recent funding activity was a Series B round of $10.7 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10.7M
- Total Rounds 1
- Last Round Series B — $10.7M
- First Round $10.7M
(Dec 2022)
- Investors Count 2
All 1 funding rounds of BiomeBank with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2022 | $10.7M | Series B | – | Ellerston Capital |
2 investors in total: 2 institutional.
Investors in BiomeBank
BiomeBank has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Ellerston Capital and SAVCF.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| savcfund.com | ||||
Diversified investment management services are provided by Ellerston Capital. | 2002 | ellerstoncapital.com | Sydney, Australia |
Investor details for BiomeBank
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BiomeBank
3 people are tracked at BiomeBank (3 in leadership).
| Name | Role | Group |
|---|---|---|
Sam Costello | Co-Founder & CEO | Leadership |
Sarah Haylock-Jacobs | Head Of Clinical Operations | Leadership |
Justin Green | Chief Financial Officer | Leadership |
Complete people profiles for BiomeBank
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BiomeBank
2 dated milestones of BiomeBank across 4 years, from founding to its latest funding, stage changes and deals.
- Founded BiomeBank is founded.
- Funding First funding round of $10.7M.
Web traffic of BiomeBank
The website of BiomeBank (biomebank.com) receives about 3.2K visits a month.
- Monthly visits3.2K
▼ 36.8% vs previous month
Websites whose visitors overlap most with BiomeBank. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
balancehealth.care | balancehealth.care | 100% | – | ||
biome-basics.com | biome-basics.com | 98% | #9,871,861 | – | |
| agilexbiolabs.com | 86% | 4.5K | #4,160,835 | View details | |
peakintegrativemed.com | peakintegrativemed.com | 82% | #1,562,983 | – | |
| sementis.com.au | 82% | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biomebank
Complete news archive for BiomeBank
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BiomeBank
BiomeBank was founded in 2018 and raised its 1st funding round 4 years after it was founded.
BiomeBank is headquartered in Thebarton, Australia. It is registered at Thebarton, South Australia, Australia.
Sam Costello is the CEO of BiomeBank, as recorded in our data. They have also founded this company.
BiomeBank is a funded company, having raised a total of $10.7M across 1 funding round to date. The company's 1st funding round was a Series B of $10.7M, raised on Dec 2022.
Founded in 2018 in Thebarton, Australia, microbial therapies are developed to address diseases, particularly recurrent Clostridioides difficile infections through BiomeBoost, which incorporates therapeutic microbes. A platform integrating microbiology, machine learning, and bioinformatics is utilized for discovering biomarkers, leads, and targets. Stool samples are collected to support research and development in the biotechnology sector.
BiomeBank offers BB265 Therapy, Donor-Derived Therapy, and Consortiome Platform.
BiomeBank has 2 investors. Key investors include Ellerston Capital, and SAVCF.